Does pertuzumab plus trastuzumab plus docetaxel increase the incidence of cardiac adverse events in patients with HER2-positive metastatic breast cancer?
The addition of pertuzumab to trastuzumab and docetaxel is well-tolerated from a cardiac standpoint in patients with HER2-positive metastatic breast cancer.
The combination of pertuzumab plus trastuzumab plus docetaxel did not increase the incidence of cardiac adverse events, including LVSD, compared with the control arm in HER2-positive MBC. The majority of cardiac adverse events were reversible.
Swain et al. (Fri,) studied this question.